Zhejiang Xinguang Pharmaceutical Co., Ltd.

SZSE:300519 Stock Report

Market Cap: CN¥1.8b

Zhejiang Xinguang Pharmaceutical Valuation

Is 300519 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 300519 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 300519 (CN¥11.01) is trading above our estimate of fair value (CN¥6.96)

Significantly Below Fair Value: 300519 is trading above our estimate of fair value.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for 300519?

Other financial metrics that can be useful for relative valuation.

300519 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue3.7x
Enterprise Value/EBITDA19.3x
PEG Ration/a

Price to Earnings Ratio vs Peers

How does 300519's PE Ratio compare to its peers?

The above table shows the PE ratio for 300519 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average52.5x
688098 Shanghai Shen Lian Biomedical
126.8xn/aCN¥1.7b
002873 Guiyang Xintian PharmaceuticalLtd
25.7x20.4%CN¥1.8b
002566 Jilin Jian Yisheng Pharmaceutical
23.8xn/aCN¥2.1b
301130 Jilin Province Xidian Pharmaceutical Sci-Tech DevelopmentLtd
33.9xn/aCN¥1.9b
300519 Zhejiang Xinguang Pharmaceutical
31xn/aCN¥1.8b

Price-To-Earnings vs Peers: 300519 is good value based on its Price-To-Earnings Ratio (31x) compared to the peer average (52.5x).


Price to Earnings Ratio vs Industry

How does 300519's PE Ratio compare vs other companies in the CN Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a18.4%
n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a18.4%
n/an/an/a
No more companies

Price-To-Earnings vs Industry: 300519 is expensive based on its Price-To-Earnings Ratio (31x) compared to the CN Pharmaceuticals industry average (27.8x).


Price to Earnings Ratio vs Fair Ratio

What is 300519's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

300519 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio31x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 300519's Price-To-Earnings Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.